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M.L. Jordan, R. Shapiro, C. Vivas, V. Scantlebury, J. McCauley, J. McMichael, P. Randhawa, 
A. Demetris, J. Fung, and T.E. Starzl 
TACROLIMUS has been shown to be an effective and 
well tolerated agent in primary solid organ transplan-
tation. I - 3 We have previously reported that an additional 
important feature of this drug is its ability to salvage renal 
allografts in patients experiencing ongoing acute rejection 
resistant to conventional antirejection therapy.-I.5 Salvage 
can be defined as a return to a defined percentage of 
baseline renal function or histologic reversal of acute 
rejection, or both. In our initial experience with 77 patients 
who developed ongoing rejection while receiving cyclospo-
rine-based immunosuppression. 57 (74%) had a successful 
outcome after conversion to tacrolimus after a follow-up of 
13.9 :!:: 9.1 months. 4 
A total of 169 patients (median age 33 years: range 2 to 
75 years: 9R males. 71 females) with ongoing rejection after 
failing baseline cyclosporine therapy have now been con-
verted to tacrolimus in an attempt to reverse rejection.(,,7 
We herein report the long-term follow-up in this group of 
patients. 
PATIENTS 
Indications for conversion 10 tacrolimus were ongoing hiopsy-
confirmed rejection in all patients after ruling out other causes of 
allograft dysfunction. as previously descnhed:"' There were iJH 
(X2'7r) primarY transplant patients. and 31 (I WI,) had undergone 
rctransplantatlon: 132 (7W;;) receIved cadavenc renal transplants 
and 37 (22'; ) n:celved grafts from living donors. The median time 
III tacrolimus conversion was 2 months (range:; days 10 55 months: 
mean 4 . .1 :!: 2.b months) after transpiantallon. Conversion was 
undertaken 12 hours after the last dose of cyclosporine. and 
cyclosporine levels continued to he monitored for 1 week. The 
initial dose of tacrolimus was 0.25 to 0.30 mg;kg;d to achieve trough 
hlood levels of 20 to 25 ng;mL in week 1. 20 ng;mL hv week 2. 15 
IlgJmL hv week 4. 10 to 15 ng.'mL hetween weeks 5 to 12. and 10 
ngJmL thcrcatler. Of the 169 pattents. 144 (Hsr'r) had received at 
kast one course of antilymphocyte therapy (OKT3: II = S9: 
;lIltilymphocyte glllhulin IALGI or antithymocyte glohulin IATGI: 
1/ = 4: OKT.1 and ALGiATG: II = 51) plus 11Igh-dose CllrticoSh:roid 
therapy pnm to conversion. Forty·seven of these patients hau 
received two or more courses of OKT3. All other patients (II = 25) 
had failed high·u,,,c corticost<:mid therapy alone. Twenty-eight 
patients ( 17r;) were dialysis-d<:pendent at the time of conversion 
owing to the severity of rejection. 
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RESULTS 
Renal Function 
At a mean follow-up of 30.0 :!:: 2.4 months (median 36.5, 
range 12 to 62 months), tacrolimus therapy was successful 
in 125 of 169 (74%) patients. who continue to have func-
tioning grafts with a mean serum creatinine level of 2.3 ± 
1.1 mgldL (Fig 1). Renal function had significantly im-
proved (P < .01) compared with preconversion values as 
early as 1 month after initiation of taerolimus therapy, and 
serum creatinine levels remained significantly reduced 
throughout the follow-up period. There was no significant 
difference in success rates between those converted from 
dual therapy (cyclosporine/prednisone. 67% success) or 
triple therapy (cyclosporine/azathioprine/prednisone, 77% 
success). Similarly. renal function at the time of conversion 
(excluding the 28 patients on dialysis) had no significant 
effect on successful outcome. Successful conversion was 
achieved in 84% of the 81 patients with preconversion 
serum creatinine levels <3 mgldL and in 73% of the 60 
patients with levels 2:3 mg/dL. 
Of the 144 patients treated with antilymphocyte prepa-
rations prior to conversion, 117 (81%) were successfully 
salvaged with tacrolimus. Furthermore. of the 28 patients 
who were dialysis-dependent at the time of conversion, 13 
(46%) had functioning grafts (mean serum creatinine 
2.15 ± 0.37 mg/dL) at a mean follow-up of 37.3 ± 16.7 
months. 
Conversion Interval 
One of the factors that significantly affected outcome was 
the time to conversion. with a higher chance of success in 
those converted carly. The mean time to conversion was 
.+.3 :!:: 2.6 months after transplantation (median 2 months. 
range 2 days to 55 months). Patients who were converted to 
tacrolimus within the first 6 months after transplantation 
From the Division of Urologic SurgeryfTransplantation and 
Starzl Transplantation Institute, University of Pittsburgh Medical 
Center. Pittsburgh. Pennsylvania. USA. 
Address reprtnt requests to M.L. Jordan. MD. Department of 
Surgery. UniverSity of Pittsburgh Medical Center. Pittsburgh. PA 
15213. 
0041-1345/99/$-see front matter 
PI! 50041-1345(99)00802-7 
81S 
82S 
Fig 1. Renal function after ta-
crolimus conversion. 
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had a significantly higher success rate than those converted 
later than 6 months (77% versus 50% success; P = .006). 
Type of Rejection 
Analysis of the 169 patients according to preconversion 
biopsy diagnosis of rejection revealed successful conversion 
in 77% of the Y I patients with acute cellular rejection alone. 
75% of the 02 patients with acute cellular rejection with 
vascular involvement. and 50% of the 16 patients with acute 
cellular rejection and primary nonfunction. Although the 
latter group fared the worst. there was no statistically 
significant difference in outcome compared with the other 
two groups. 
Table 1. Outcome After Conversion to Tacrolimus in High- and 
Low-Risk Patients 
Low-Risk High-Risk Total 
(n = 70) (n = 99) In = 169) 
Retransplantation 6(9%) 25 (25%) 31 (18%) 
Patient survIVal (%) 
6 months 96 95 95 
1 year 96 94 95 
3 years 96 93 94 
Graft survival (%) 
6 months 87 76 80 
1 year 84 70 76 
3 years 83 68 74 
CytomegaloVIrus 2 5 4 
Infection (%) 
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Concomitant Therapy 
In the 125 patients successfully converted to tacrolimus, 
prednisone doses were reduced from a mean of 28.0 :!: 9.0 
mg/d (range 4 to 60 mg/d) before conversion to 8.5 :!: 4.1 
mg/d (range 2.5 to 20 mg/d) postconversion. A total of 28 of 
125 (22%) patients are currently receiving no corticoste-
roids. and the dose was reduced in a further 87 (70%) 
patients. Furthermore. in the 87 patients who were receiv-
ing azathioprine preconversion. 39 (45%) are no longer 
receiving this agent. and the dose has been reduced in a 
further 24 patients. The mean dose of tacrolimus in the 
successful cases was 19.3 :!: 9.1 mg/d at the time of 
conversion, which was reduced to 11.3 :!: 6.8 mg/d (P < .01) 
at the latest follow-up. 
High- Versus Low-Risk Patients 
Treatment of ongoing rejection was found to be effective in 
high-risk (n = qq) as well as low-risk patients (n = 70). 
High-risk patients included those on dialysis at the time of 
conversion. patients with baseline serum creatinine levels 
>5.0 mg/dL. those who had undergone >2 retransplants. 
patients >6 months posttransplant at the time of conver-
sion. and pediatric patients « 13 years). As expected. there 
were more retransplantations and a trend toward reduced 
3-year graft survival in the high-risk group (Table I). but 
given the high-risk circumstances at the time of conversion. 
this outcome can be regarded as very acceptable compared 
with the low-risk group. 
• 
LONG-TERM OUTCOME AFTER TACROLIMUS CONVERSION 
DISCUSSION 
'Rescue' or 'conversion' therapy from one baseline immu-
nosuppressive regimen to another to salvage grafts with 
ongoing rejection is a new concept since the cyclosporine 
era. The aims of optimal conversion therapy should be to 
preserve renal function. maintain patient safety, avoid 
overimmunosuppression. and achieve satisfactory long-
term graft outcome. Since our initial reports of successful 
treatment of rejecting renal allografts with tacrolimus, 
other single- and multicenter studies have confirmed our 
original observations.8 - 11 This long-term experience dem-
onstrates that tacrolimus has sustained efficacy as conver-
sion therapy for ongoing renal allograft rejection with 
salvage rates identical to those reported earlier in a smaller 
group of patients and is effective in both low- and high-risk 
patients. Furthermore. corticosteroid tapering and tacroli-
mus monotherapy are achievable over the long-term. Based 
on these data. we recommend that conversion to tacrolimus 
be performed prior to increasing conventional anti rejection 
treatment of renal transplants under primary cyclosporine-
based therapy. 
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